
The USA is preparing to release $600 million in congressional funding for Gavi, the Vaccine Alliance, ending months of uncertainty over Washington's support for the global immunization body. The money, appropriated for the 2025 and 2026 fiscal years, had been held back amid a dispute over vaccine safety and how the alliance chooses and buys its shots.
Gavi's board will decide exactly how the funds are spent, but malaria vaccination across sub-Saharan Africa is expected to be a leading priority. The alliance is facing a budget shortfall of about $1.9 billion, and has said the American contribution is vital for preventive campaigns against diseases such as cholera and for keeping global vaccine stockpiles topped up.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze